Pretransplantation Conditioning Influence on the Occurrence of Cyclosporine or FK-506 Neurotoxicity in Allogeneic Bone Marrow Transplantation

References

1. ↵
   Joss DV, Barrett AJ, Kendra JR, Lucas CF, Desai S. Hypertension and convulsions in children receiving cyclosporin A [letter]. Lancet 1982 .i:906
2. ↵
   Boogaerts MA, Zachee P, Verwilghen RL. Cyclosporin, methylprednisolone, and convulsions [letter]. Lancet 1982 .ii ;1216–1217
3. ↵
   Dieperink H, Moller J. Cyclosporin A, methylprednisolone, and convulsions (letter). Lancet 1982 .ii ;1217
4. ↵
   Durrant S, Chipping PM, Palmer S, Gordon-Smith EC (letter). Lancet 1982;829–830
5. Noll RB, Kulkarni R. Complex visual hallucinations and cyclosporine. Arch Neurol 1984;41:329–330

   CrossRefPubMedWeb of Science
6. ↵
   Shah D, Rylance PB, Rogerson ME, Bewick M, Parsons V. Generalized epileptic fits in renal transplant recipients given cyclosporin A. BMJ 1984;289:1347–1348
7. Atkinson K, Biggs J, Phil D, et al. Cyclosporine-associated central-nervous-system toxicity after allogeneic bone-marrow transplantation. N Engl J Med 1984;38:527
8. ↵
   Kahan BD, Wideman CA, Flechner S, Van Buren CT. Anaphylactic reaction to intravenous cyclosporin (letter). Lancet 1984 .i ;52
9. ↵
   Thompson CB, Sullivan KM, June CH, Thomas ED. Association between cyclosporin neurotoxicity and hypomagnesemia. Lancet 1984 .ii:1116–1120
10. Powell-Jackson PR, Carmichael FJL, Calne RY, Williams R. Adult respiratory distress syndrome and convulsions associated with administration of cyclosporine in liver transplant recipients. Transplantation 1984;38:341–343

    PubMedWeb of Science
11. Wilczek H, Ringden O, Tyden G. Cyclosporine-associated central nervous system toxicity after renal transplantation. Transplantation 1984;39:110
12. Atkinson K, Biggs J, Darveniza P, Boland J, Concannon A, Dodds A. Cyclosporine-associated central nervous system toxicity after allogeneic bone marrow transplantation. Transplantation 1984;38:34–37

    PubMed
13. Sloane JP, Lwin KY, Gore ME, Powles RL, Smith JF. Disturbance of blood-brain barrier after bone-marrow transplantation (letter). Lancet 1985 .ii ;280–281
14. Velu T, Debusscher L, Stryckmans PA. Cyclosporin-associated fatal convulsions (letter). Lancet 1985 .i:219
15. ↵
    Beaman M, Parvin S, Veitch PS, Walls J. Convulsions associated with cyclosporin A in renal transplant recipient. BMJ 1985;290:139–140
16. ↵
    Berden JHM, Hoitsma AJ, Merx JL, Keyser A. Severe central-nervous-system toxicity associated with cyclosporin (letter). Lancet 1985 .i:219–220
17. ↵
    Rubin AM, Kang H. Cerebral blindness and encephalopathy with cyclosporin A toxicity. Neurology 1987;37:1072–1076

    Abstract/FREE Full Text
18. ↵
    de Groen PC, Aksamit AJ, Rakela J, Forbes GS, Krom RAF. Central nervous system toxicity after liver transplantation: the role of cyclosporin and cholesterol. N Engl J Med 1987;317:861–866

    CrossRefPubMedWeb of Science
19. Bhatt BD, Meriano FV, Buchwald D. Cyclosporine-associated central nervous system toxicity. N Engl J Med 1988;318:788–789

    PubMed
20. Hoefnagels WAJ, Gerritsen EJA, Brouwer OF, Souverijn JHM. Cyclosporin encephalopathy associated with fat embolism induced by the drug’s solvent. Lancet 1988 :901
21. ↵
    Wilson SE, de Groen PC, Aksamit AJ, Wiesner RH, Garrity JA, Krom RAF. Cyclosporin A-induced reversible cortical blindness. J Clin Neuroophthalmol 1988;8:215–220

    PubMed
22. Lane RJM, Roche SW, Leung AAW, Greco A, Lange LS. Cyclosporin neurotoxicity in cardiac transplant recipients. J Neurol Neurosurg Psychiatry 1988;51:1434–1437

    Abstract/FREE Full Text
23. ↵
    Scheinman SJ, Reinitz ER, Petro G, Schwartz RA, Szmalc FS. Cyclosporine central neurotoxicity following renal transplantation: report of a case using magnetic resonance images. Transplantation 1990;49:215–216

    PubMed
24. ↵
    Lucey MR, Kolars JC, Merion RM, Campbell DA, Aldrich M, Watkins PB. Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450 IIIA. Lancet 1990;335:11–15

    CrossRefPubMedWeb of Science
25. ↵
    Ghalie R, Fitzsimmons WE, Bennett D, Kaizer H. Cortical blindness: a rare complication of cyclosporine therapy. Bone Marrow Transplant 1990;6:147–149

    PubMedWeb of Science
26. ↵
    Lloveras JJ, Larrue V, Suc E, Fourtanier G, Durand D. Leukoencephalopathy after cyclosporine in a liver transplant. Clin Transplant 1990;4:58–62
27. ↵
    Reece DE, Frei-Lahr DA, Shepherd JD, et al. Neurologic complications in allogeneic bone marrow transplant patients receiving cyclosporin. Bone Marrow Transplant 1991;8:393–401

    PubMedWeb of Science
28. ↵
    Truwit CL, Denaro CP, Lake JR, DeMarco T. MR imaging of reversible cyclosporin A-induced neurotoxicity. AJNR Am J Neuroradiol 1991;12:651–659

    Abstract/FREE Full Text
29. ↵
    Nussbaum ES, Maxwell RE, Bitterman PB, Hertz MI, Bula W, Latchaw RE. Cyclosporine A toxicity presenting with acute cerebellar edema and brainstem compression. J Neurosurg 1995;82:1068–1070

    PubMedWeb of Science
30. ↵
    Schwartz RB, Bravo SM, Klufas RA, et al. Cyclosporine neurotoxicity and its relationship to hypertensive encephalopathy: CT and MR findings in 16 cases. AJR Am J Roentgenol 1995;165:627–631

    CrossRefPubMedWeb of Science
31. ↵
    Bartynski WS, Grabb BC, Zeigler Z, Lin L, Andrews DF. Watershed imaging features of clinical vascular injury in cyclosporin A neurotoxicity. J Comput Assist Tomogr 1997;21:872–880

    CrossRefPubMed
32. ↵
    Jansen O, Krieger D, Krieger S, Sartor K. Cortical hyperintensity on proton density-weighted images: an MR sign of cyclosporine-related encephalopathy. AJNR Am J Neuroradiol 1996;17:337–344

    Abstract
33. ↵
    Zimmer WE, Hourihane JM, Wang HZ, Schriber JR. The effect of human leukocyte antigen disparity on cyclosporin neurotoxicity after allogeneic bone marrow transplantation. AJNR Am J Neuroradiol 1998;19:601–608

    Abstract
34. ↵
    Zoja C, Furci L, Ghilardi F, et al. Cyclosporin-induced endothelial cell injury. Lab Invest 1986;55:455–462

    PubMedWeb of Science
35. ↵
    Wijdicks EFM. Neurologic manifestations of immunosuppressive agents. In: Wijdicks EFM, ed. Neurologic Complications in Organ Transplant Recipients. Boston, MA: Butterworth-Heinemann,1999;127–140
36. ↵
    Holler E, Kolb HJ, Hiller E, et al. Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation. Blood 1989;73:2018–2024

    Abstract/FREE Full Text
37. ↵
    Scherrer U, Vissing SF, Morgan BJ, et al. Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. N Engl J Med 1990;323:693–699

    CrossRefPubMedWeb of Science
38. ↵
    Mark AL. Editorial: Cyclosporine, sympathetic activity, and hypertension. N Engl J Med 1990;323:748–750

    PubMedWeb of Science
39. ↵
    Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996;334:494–500

    CrossRefPubMedWeb of Science
40. Provenzale JM, Petrella JR, Cruz LC, et al. Quantitative assessment of diffusion abnormalities in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol 2001;22:1455–1461

    Abstract/FREE Full Text
41. Mukherjee P, McKinstry RC. Reversible posterior leukoencephalopathy syndrome: evaluation with diffusion-tensor MR imaging. Radiology 2001;219:756–765

    CrossRefPubMedWeb of Science
42. ↵
    Covarrubias DJ, Leutmer PH, Campeau NG. Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images. AJNR Am J Neuroradiol 2002;23:1038–1048

    Abstract/FREE Full Text
43. ↵
    Ay H, Buonanno FS, Schaefer PW, et al. Posterior leukoencephalopathy without severe hypertension: utility of diffusion-weighted MRI. Neurology 1998;51:1369–1376

    Abstract/FREE Full Text
44. ↵
    Ito Y, Arahata Y, Goto Y, et al. Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. AJNR Am J Neuroradiol 1998;19:415–417

    Abstract
45. ↵
    Osborn AG. Infection, white matter abnormalities, and degenerative diseases (part 4). In: Osborne AG, ed. Diagnostic Neuroradiology. St. Louis, MO: Mosby-Year Book, Inc.,1994 :764–766
46. ↵
    Bartynski WS, Zeigler Z, Spearman MP, Lin L, Shadduck RK, Lister J. Etiology of cortical and white matter lesions in cyclosporin-A and FK-506 neurotoxicity. AJNR Am J Neuroradiol 2001;22:1901–1914

    Abstract/FREE Full Text
47. ↵
    Zeigler ZR, Shadduck RK, Nemunaitis J, Andrews DF, Rosenfeld CS. Bone marrow transplant-associated thrombotic microangiopathy: a case series. Bone Marrow Transplant 1995;15:247–253

    PubMedWeb of Science
48. ↵
    Silva VA, Frei-Lahr D, Brown RA, Herzig GP. Plasma exchange and vincristine in the treatment of hemolytic uremic syndrome/thrombotic thrombocytopenic purpura associated with bone marrow transplantation. J Clin Apheresis 1991;6:16–20

    CrossRefPubMed
49. ↵
    Carlson K, Smedmeyr B, Hagberg H, Oberg G, Simonsson B. Haemolytic uraemic syndrome and renal dysfunction following BEAC (BCNU, etoposide, Ara C, cyclophosphamide) ± TBI and auto-BMT for malignant lymphomas. Bone Marrow Transplant 1993;11:205–208

    PubMed
50. ↵
    Jones RJ, Lee KSK, Beschorner WE, et al. Venocclusive disease of the liver following bone marrow transplantation. Transplantation 1987;44:778

    PubMedWeb of Science
51. ↵
    Fung JJ, Todo S, Tzakis A, et al. Current status of FK 506 in liver transplantation. Transplant Proc 1991;23:1902–1908

    PubMedWeb of Science
52. ↵
    Colvin OM. Antitumor alkylating agents. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer Principles & Practice of Oncology, 6th ed. Philadelphia, PA: Lippincott Williams& Wilkins,2001 :363–376
53. ↵
    Johnson SW, Stevenson JP, O’Dwyer PJ. Cisplatin and its analogues. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer Principles & Practice of Oncology 6th ed. Philadelphia, PA: Lippincott Williams& Wilkins,2001 :376–388
54. ↵
    Chu E, Mota AC, Fogarasi MC. Antimetabolites. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer Principles & Practice of Oncology 6th ed. Philadelphia, PA: Lippincott Williams& Wilkins,2001 :388–415
55. ↵
    Stewart CF, Ratain MJ. Topoisomerase interactive agents. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer Principles & Practice of Oncology 6th ed. Philadelphia, PA: Lippincott Williams& Wilkins,2001 :415–452
56. ↵
    Ratain M. Pharmacokinetics and pharmacodynamics. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer Principles & Practice of Oncology 6th ed. Philadelphia, PA: Lippincott Williams& Wilkins,2001 :335–345
57. ↵
    Hellman S. Principles of cancer management: radiation therapy. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer Principles & Practice of Oncology 6th ed. Philadelphia, PA: Lippincott Williams& Wilkins,2001 :265–289
58. ↵
    Zeigler ZR, Rosenfeld CS, Andrews III DF, et al. Plasma von Willebrand factor antigen (vWF:AG) and thrombomodulin (TM) levels in adult thrombotic thrombocytopenic purpura/hemolytic uremic syndromes (TTP/HUS) and bone marrow transplant-associated thrombotic microangiopathy (BMT-TM). Am J Hematol 1996;53:213–220

    CrossRefPubMedWeb of Science
59. ↵
    Fajardo LF. The complexity of endothelial cells. Am J Clin Pathol 1989;92:241–250

    PubMedWeb of Science
60. ↵
    Wright HP. Mitosis patterns in aortic endothelium. Atherosclerosis 1972;15:93–100

    CrossRefPubMedWeb of Science
61. ↵
    Schwartz SM, Benditt EP. Cell replication in the aortic endothelium: a new method for study of the problem. Lab Invest 1973;28:699–707

    PubMed
62. ↵
    Schwartz SM, Benditt EP. Aortic endothelial cell replication: effects of age and hypertension in the rat. Circ Res 1977;41:248–255

    Abstract/FREE Full Text
63. Spaet TH, Lejnieks I. Mitotic activity of rabbit blood vessels. Proc Soc Exp Mol Biol Med 1967;125:1197–1201
64. Tannock IF, Hayashi S. The proliferation of capillary endothelial cells. Cancer Res 1972;32:77–82

    Abstract/FREE Full Text
65. D’Amore PA, Braunhut SJ. Stimulatory and inhibitory factors in vascular growth control. In: Ryan US, ed. Endothelial Cells Boca Raton, Fl: CRC Press;1988 :13–36
66. ↵
    Heimark RL, Schwartz SM. Endothelial morphogenesis. In: Simionescu N, Simionescu M, eds. Endothelial Cell Biology in Health Disease New York, NY: Plenumm Press;1988 :123–143
67. ↵
    Davies PF, Remuzzi A, Gordon EJ, Dewey CR Jr. Turbulent fluid shear stress induces vascular endothelial cell turnover in vitro. Proc Natl Acad Sci U S A 1986;83:2114–2117

    Abstract/FREE Full Text
68. ↵
    Reinhold HS, Buisman GH. Radiosensitivity of capillary endothelium. Br J Radiol 1973;46:54–57

    Abstract/FREE Full Text
69. ↵
    Martin DF, Fischer JJ. Radiation sensitivity of cultured rabbit aortic endothelial cells. Int J Radiat Oncol Biol Phys 1984;10:1903–1906

    PubMed
70. Penhaligon M, Laverick M. Radiation response of endothelial cells in vitro. Br J Radiol 1985;58:913–914

    Abstract/FREE Full Text
71. ↵
    Rhee JG, Lee I, Song CW. The clonogenic response of bovine aortic endothelial cells in culture to radiation. Radiat Res 1986;106:182–189

    CrossRefPubMed
72. Fajardo LF, Stewart JR. Experimental radiation-induced heart disease. Am J Pathol 1970;59:299–314

    PubMedWeb of Science
73. ↵
    Phillips TL. An ultrastructural study of the development of radiation injury in the lung. Radiology 1966;87:49–54

    CrossRefPubMedWeb of Science
74. ↵
    Sheline GE, Wara WM, Smith V. Therapeutic irradiation and brain injury. Int J Radiat Oncol Biol Phys 1980;6:1215–1228

    CrossRefPubMedWeb of Science
75. Fajardo LF. Morphology of radiation effects on normal tissues. In: Principles and Practice of Radiation Oncology, 3rd ed. Philadelphia, Pa: Lippencott-Raven;1977 :143–154
76. ↵
    Sauer R. Radiation therapy of brain tumors. In: Therapy of Malignant Brain Tumors. New York, NY: Springer-Verlag;1987 :250–273
77. ↵
    Rippe DJ, Edwards MK, Schrodt Bognanno JR, D’Amour PG, Boyko OB. Reversible cerebral lesions associated with Tiazofurin usage: MR demonstration. J Comput Assist Tomogr 1988;12:1078–1081

    PubMed
78. Heran F, Defer G, Brugieres P, et al. Cortical blindness during chemotherapy: clinical, CT and MR correlations. J Comput Assist Tomogr 1990;14:262–266

    PubMed
79. ↵
    Vaughn DJ, Jarvik JG, Hackney D, Peters S, Stadtmauer EA. High dose cytarabine neurotoxicity: MR findings duriung acute phase. AJNR Am J Neuroradiol 1993;14:1014–1016

    Abstract/FREE Full Text
80. Mihatsch MJ, Thiel G, Ryffel B. Histopathology of cyclosporine nephrotoxicity. Transplant Proc 1988;20:759–771

    PubMedWeb of Science
81. Remuzzi G, Bertani T. Renal vascular and thrombotic effects of Cyclosporine. Am J Kidney Dis 1989;13:261–272

    PubMedWeb of Science
82. Kon V, Sugiura M, Inagami T, Harvie BR, Ichkawa I, Hoover RL. Role of endothelin in cyclospoine-induced glomerular dysfunction. Kidney Int 1990;37:1487–1491

    PubMedWeb of Science
83. ↵
    Shireman PK, Pearce WH. Endothelial cell function: biological and physiologic functions in health and disease. AJR Am J Roentgenol 1996;166:7–13

    PubMed
84. Jaffe EA. Cell biology of endothelial cells. Hum Pathol 1987;18:234–239

    PubMedWeb of Science
85. ↵
    Davies MG, Hagen PO. The vascular endothelium. Ann Surg 1993;218:593–609

    PubMedWeb of Science
86. ↵
    Shweiki D, Ahuva I, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogensis. Nature 1992;359:843–845

    CrossRefPubMedWeb of Science
87. Levy AP, Levy NS, Wegner S, et al. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 1995;270:13333–13340

    Abstract/FREE Full Text
88. Kevil CG, Payne DH, Mire E, et al. Vascular permeability factor/vascular endothelial cell growth factor-mediated permeability occurs through disorganization of endothelial tight junctional proteins. J Biol Chem 1998;273:15099–15103

    Abstract/FREE Full Text
89. Schoch HJ, Silvia F, Marti HH. Hypoxia-induced vascular endothelial growth factor expression causes vascular leakage in the brain. Brain 2002;125:2549–2557

    Abstract/FREE Full Text
90. Chavez JC, Agani F, Pichiule et al. Expression of hypoxia-inducible factor 1α in the brain of rats during chronic hypoxia. J Appl Physiol 2000;89:1937–1942

    Abstract/FREE Full Text
91. ↵
    Olesen SP. Rapid increase in blood-brain barrier permeability during severe hypoxia and metabolic inhibition. Brain Res 1986;368:24–29

    CrossRefPubMedWeb of Science